Companies › Galderma R&D
2 active drug programs in 7 registered trials: 4 Phase 3, 3 Phase 2; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nemolizumab Interleukin-31 receptor subunit alpha inhibitor | IL31RA | Phase 3 | Moderate-to-Severe Atopic Dermatitis; Prurigo Nodularis; Atopic Dermatitis; Chronic Pruritus of Unknown Origin … | Dec 2026 |
| Trifarotene Retinoic acid receptor gamma agonist | RARG | Phase 3 | Acne Vulgaris | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03989206 | Nemolizumab | Phase 3 | Moderate-to-Severe Atopic Dermatitis | Immunology | Aug 2026 |
| NCT04204616 | Nemolizumab | Phase 3 | Prurigo Nodularis | Immunology | Oct 2026 |
| NCT07074977 | Nemolizumab | Phase 2 | Chronic Pruritus of Unknown Origin | Immunology | Dec 2026 |
| NCT07186413 | Trifarotene | Phase 3 | Acne Vulgaris | Immunology | Dec 2026 |
| NCT07762833 | Nemolizumab | Phase 3 | Atopic Dermatitis | Immunology | Oct 2027 |
| NCT07047690 | Nemolizumab | Phase 2 | Systemic Sclerosis | Immunology | May 2028 |
| NCT07660835 | Nemolizumab | Phase 2 | Moderate-to-Severe Atopic Dermatitis | Immunology | Jul 2028 |
LEO Pharma Integrative Skin Science and Research Pharvaris Netherlands Chengdu Kangnuoxing Biopharma AUG Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.